QDX HealthID to Support Saliva/Sputum-based COVID-19 Diagnostic Services Developed by MicroGenDX

The QDX^TM HealthID service works with MicroGenDX test kits,
which allow for easy collection of saliva samples

San Marcos, TX, July 15, 2020 (GLOBE NEWSWIRE) -- QDX HealthID Incorporated, a wholly-owned subsidiary of Quantum Materials Corp (OTC Bulletin Board: QTMM) – today announced that its parent has signed an agreement to include MicroGenDX diagnostic services as part of the QDX^TM HealthID ecosystem. The QDX HealthID, currently in beta release, is a SaaS-based platform that allows companies and individuals to see and select a particular COVID-19 test kit, authenticate and record the test results in a secure way, and then share those authenticated results with friends, family—or any other third party of their choosing.

The agreement signed with MicroGenDX allows those persons registered on the QDX^TM HealthID platform the convenience of saliva/sputum-based COVID-19 diagnostic services that the MicroGenDX molecular diagnostic lab is known for— when a health care provider prescribes MicroGenDX’s test.

https://microgendx.com/covid19/

The agreement is non-exclusive and allows for other registered test kits and diagnostic services to be used by QDX^TM HealthID customers. The QDX^TM HealthID service operates in conjunction with test companies and diagnostic services companies.

"We are delighted to be working with MicroGenDX and making its easy-to-administer, FDA-authorized saliva/sputum specimen test available to our QDX^TM HealthID customers," says Stephen B. Squires, CEO of QDX HealthID. "Our combined capabilities will allow companies to offer attractive back-to-work programs that give their employees a choice of testing options.”

“MicroGenDX is excited to register its test kits and diagnostic services on the innovative QDX^TM HealthID service. MicroGenDX has pioneered the use of saliva/sputum samples for COVID-19 testing, and sputum collection and views the QDX^TM Health ID service as a value-add for physicians who prescribe our tests and a convenience for consumers.” notes MicroGenDX CEO Rick Martin.

MicroGenDX has received Emergency Use Authorization from the U.S. Food and Drug Administration under Section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §360bbb-3), for its sputum and NP swab test, and inclusion of the Southwest Regional PCR Laboratory dba MicroGenDX as an authorized lab for COVID-19 testing.

The QDX^TM HealthID service allows an individual to control when and how to share an authenticated health status, such as the result of a COVID-19 test, without revealing the test result itself. QDX^TM HealthID’s guiding mantra is “We don’t share your data. You do.”